in biochemistry from the University of Birmingham, UK with a B.Sc.
(Hons.) then obtained a Ph.D. while working in industry in
conjunction with the London School of Hygiene & Tropical
Medicine researching the mode of action of metronidazole in the
parasite and host
industrial career covering over 40 years, initially with several
European pharmaceutical companies in the UK plus assignments in
Italy, Sweden and ultimately the US, most recently as Vice President
DMPK, Roche, Palo Alto, CA
of working with European, US and Japanese mid to large size
pharmaceutical and biotech companies including Pharmacia/Pfizer,
Amgen and Daiichi
pharmacokinetics and metabolism laboratories of over 100 staff
supporting both small and large molecule discovery and development
areas include oncology, CNS, metabolic disease, inflammation,
cardiovascular and anti-infectives, including anti-viral
to 11 global/US and 13 European successful registrations of new
medicines whilst working in the pharmaceutical industry
and President of RMI-Pharmacokinetics supporting a substantial
client base from biotechnology, pharmaceutical, CRO and venture
capital companies throughout the US, Canada, Europe and Asia
in the scientific community including past member of the editorial
boards or reviewer for Xenobiotica, Biopharm. & Drug Dis.,
Current Drug Metabolism, J. Pharmacokin. & Biopharm, Eur. J.
Clin. Pharm, Brit. J. Clin. Pharm. and J. Pharm. Pharmacol. Current
reviewer for J. Pharm Sci., Brit. J. Clin. Pharmacol., Bioanalysis
and J. Pharm. Expatal Ther. Also past Chairperson of the DMDG (UK),
joint founder of the societies, PK-UK and DMDG (Italy) and guest
editor for Bioanalysis
over 80 publications, including several book chapters, and given
over 120 presentations/training courses throughout the world
Ings, R.M.J. McFadzean,
J.A. and Ormerod, W.E. (1974) The mode of action of metronidazole in
and other microorganisms. Biochem. Pharm., 23,1421-1429.
Ings, R.M.J. and Stevens,
L.A. (1983) The pharmacokinetics and metabolism of diuretics in
'Progress in Drug Metabolism' vol 7, Ed. Bridges, J.W. and
Chasseaud, L.F., John Wiley & Sons, Chichester, pp 57-171.
Ings, R.M.J. (1984)
Melanin binding of drugs and its implications. Drug Metab. Rev., 15,
Ings, R.M.J. (1984) Animal
studies and the bioavailability testing of drug products in
'Controlled drug bioavailability' vol.2., Ed. Smolen, V.F. and Ball,
L., John Wiley and Sons Inc., New York pp 43 - 89.
Ings, R.M.J., Reeves,
D.S., White, L.O., Bax, R.P., Bywater, M.B. and Holt, H.A. (1985).
The human pharmacokinetics of cefotaxime and its metabolites and the
role of renal tubular secretion on their elimination. J.
121 - 142.
Ings, R.M.J. (1989).
Pharmacokinetics and its application to Drug Development. In
'Xenobiotic Metabolism & Disposition : The Design of Studies on
Novel Compounds' Ed Illing, H.P.A., CRC Press Inc, Boca Raton,
Florida, pp 99 - 146.
Ings R.M.J. (1990).
Interspecies Scaling and Comparison in Drug Development and
Toxicokinetics. Xenobiotica, Special Issue, 20,1201-1231.
Ings, R.M.J. (1994).
Pharmacokinetics. In 'Medicinal Chemistry - Principles and Practice'
Ed. King, F.D., The Royal Society of Chemistry, Cambridge, UK, pp 67
Ings, R.M.J. (1995).
Pharmacokinetics: In 'Encyclopedia of Analytical Sciences' Ed.
Townsend, A., Academic Press, London, UK, pp 3893 - 3928.
Zhang, J.Y., Zhan, J.,
Cook, C., Ings, R. and Breau, A.P. (2003). Involvement of human
UGT2B7 and 2B15 in rofecoxib metabolism J. Drug Met. & Disp. 31,
McLean, M.A., Tam C-Y.,
Baratta, M.T., Holliman, C.L., Ings, R.M. and Galluppi G.R. (2007).
Accelerating Drug Development: Methodogy to support accelerating
First-in-Man pharmacokinetic studies by the use of drug candidate
microdosing Drug. Dev. Res., 67,
R.M.J. (2009). Microdosing: a valuable tool for accelerating drug
development and the role of bioanalytical development methods in
meeting the challenge. Bioanalysis, 1,